Figure 6: The potency of the antibody produced by the Ang II vaccine on cardiac dysfunction after MI. | Scientific Reports

Figure 6: The potency of the antibody produced by the Ang II vaccine on cardiac dysfunction after MI.

From: A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction

Figure 6

(a) The protocol to evaluate the potency of immunized serum administration on cardiac dysfunction induced by MI. (b) The serum anti-Ang II antibody titer. MI + control serum, n = 7; MI + immunized serum, n = 7; MI + immunized serum + Ang II, n = 7. *p < 0.05 by the Tukey–Kramer post hoc test. (c) Representative M-mode echocardiograms on day 35. A quantitative analysis of (d) the left ventricular ejection fraction and (e) the end-systolic left ventricular diameter. MI + control serum, n = 7; MI + immunized serum, n = 7; MI + immunized serum + Ang II, n = 7. *p < 0.05 by the Tukey–Kramer post hoc test. (f) The correlation between the left ventricular ejection fraction and the serum anti-Ang II antibody titer in the MI + immunized serum and MI + immunized serum + Ang II groups.

Back to article page